中国药物警戒 ›› 2020, Vol. 17 ›› Issue (1): 17-22.
DOI: 10.19803/j.1672-8629.2020.01.04

• 临床研究 • 上一篇    下一篇

奥沙利铂联合替吉奥与奥沙利铂联合卡培他滨用于胃癌新辅助化疗后不良反应的比较

朱佳丽1, 周永宁2, 袁文臻3, 颉晓铭1, 关泉林1,*   

  1. 1兰州大学第一临床医学院,甘肃 兰州,730000;
    2兰州大学第一医院消化内科,甘肃省胃肠病重点实验室,甘肃 兰州 730000;
    3兰州大学第一医院肿瘤科,甘肃 兰州 730000
  • 收稿日期:2019-04-15 修回日期:2020-01-15 出版日期:2020-01-15 发布日期:2020-01-15
  • 通讯作者: *关泉林,男,博士,教授,胃肠道及甲状腺肿瘤的临床诊治。E-mail:guanquanlin@163.com
  • 作者简介:朱佳丽,女,在读硕士,肿瘤学及胃肠道肿瘤的临床诊治。
  • 基金资助:
    国家重点研发计划（2017YFC0908300）：规范化大型胃癌队列的建立及可行性研究

Comparison of Adverse Reactions after Neoadjuvant Chemotherapy with SOX and XELOX for Gastric Cancer

ZHU Jiali1, ZHOU Yongning2, YUAN Wenzhen2, XIE Xiaoming1, GUAN Quanlin1,*   

  1. 1The First Clinical Medical College of Lanzhou University, Lanzhou Gansu 730000 China;
    2Department of Gastroenterology, the First Hospital of Lanzhou University, Gansu Key Laboratory of Gastroenterology, Lanzhou Gansu 730000, China;
    3Department of Oncology, the First Hospital of Lanzhou University, Lanzhou Gansu 730000, China
  • Received:2019-04-15 Revised:2020-01-15 Online:2020-01-15 Published:2020-01-15

PDF (PC)

315

摘要： 目的 比较奥沙利铂联合替吉奥（SOX）与奥沙利铂联合卡培他滨（XELOX）应用于胃癌新辅助化疗后不良反应的差异。方法 记录兰大一院肿瘤科接受SOX、XELOX方案新辅助化疗3周期后不良反应的指标变化及发生情况。利用spss22.0软件,定量定性比较两种方案新辅助化疗后的不良反应。结果 共纳入符合标准的胃癌患者97例,SOX组68例,XELOX组29例。就化疗后骨髓抑制,化疗后红细胞的下降程度XELOX组高于SOX组,差异有统计学意义（P=0.008）;化疗后其他血液系统指标下降的程度相当,差异无统计学意义（P>0.05）;化疗后XELOX组更易导致白细胞及中性粒细胞减少,差异有统计学意义（P<0.05）;就化疗后肝、肾功能损害,指标的升高程度及发生率均未见明显统计学差异（P>0.05）;两种方案化疗后胃肠道及其他不良反应（黏膜炎、手足综合征等）的发生,未见明显差异（P>0.05）。结论 XELOX新辅助化疗方案更容易导致化疗后骨髓抑制的发生,且化疗后红系下降的程度明显高于SOX组。就安全性而言,临床更推荐SOX方案用于胃癌的新辅助化疗。

关键词: 胃癌, 新辅助化疗, SOX, XELOX, 不良反应

Abstract: Objective To compare the difference between SOX (oxaliplatin combined with sergio) and XELOX (oxaliplatin combined with capecitabine) in the incidence of adverse reactions after neoadjuvant chemotherapy for gastric cancer. Methods Changes in indicators and occurrence of adverse reactions after 3 cycles of SOX and XELOX neoadjuvant chemotherapy were recorded. Spss22.0 software was used to quantitatively and qualitatively compare the adverse reactions after neoadjuvant chemotherapy. Results A total of 97 patients with gastric cancer who met the criteria were included, including 68 cases in the SOX group and 29 cases in the XELOX group. In terms of bone marrow suppression after chemotherapy, erythrocytes decreased more significantly in the XELOX group than in the SOX group, and the difference was statistically significant (P =0.008). After chemotherapy, other indexes of the blood system decreased to a similar extent, and the difference was not statistically significant (P >0.05). After chemotherapy, the XELOX group was more vulnerable to leukopenia and neutropenia, and the difference was statistically significant (P<0.05).There was no statistically significant difference in the degree and incidence of liver and kidney function damage after chemotherapy (P>0.05). There was also no significant difference in the occurrence of gastrointestinal or other adverse reactions (mucositis, hand-foot syndrome, etc.) after chemotherapy between the two regimens (P>0.05).Conclusion XELOX neoadjuvant chemotherapy is more likely to induce bone marrow suppression after chemotherapy, and the decline in red blood cells after chemotherapy is more significant than in the SOX group. In terms of safety, SOX protocol is preferable as a neoadjuvant chemotherapy of gastric cancer in clinic.

Key words: gastric cancer, neoadjuvant chemotherapy, SOX, XELOX, .adverse reactions

中图分类号: